Sjögren’s Team to Accelerate Medicines
Official title: Sjögren’s Team for Accelerating Medicines Partnership (STAMP)
Funded at University of California, San Francisco · NIH-11601030 · Data updated 2026-11-12
A team at UC San Francisco is coordinating a study to better understand Sjögren’s syndrome and speed up the development of better tests and treatments for people with the condition.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project start | September 3, 2026 |
| Project end | December 31, 2026 |
| Funding year | 2026 |
| Award (this year) | $1,000,000 |
| NIH project number | 3UC2DE032254-05S1 |
| Project ID | NIH-11601030 on NIH RePORTER |
Who could benefit from this research
✓Could help
People with Sjögren’s syndrome, including those with gland-related and extraglandular manifestations, who consent to participate and provide biospecimens.
✕Less likely to help
Patients not interested in contributing samples or sharing data may not directly benefit.
What this research studies
This project brings together experts in autoimmunity to build a deeply characterized group of Sjögren’s patients and to link their clinical data with genetic, molecular, and epidemiologic information. Researchers will use existing patient cohorts, add new participants, and collect stored biospecimens to create a rich resource. The goal is to unlock pathogenetic mechanisms and identify targets for future therapies that could improve diagnosis, monitoring, and treatment for Sjögren’s patients. Participants may contribute by providing samples and sharing medical information, with careful oversight and consent.
Why it matters
Potential benefit: If successful, patients with Sjögren’s could benefit from faster development of accurate diagnostics and more effective, targeted treatments.
How similar studies have gone: Previous large Sjögren’s cohorts have shown that integrated clinical and molecular data can reveal disease pathways and guide therapy; this project aims to build on that approach.
Where this research is happening
-
University of California, San Francisco
San Francisco, United States Active
Researchers
- Principal investigator: Shiboski, Caroline Helene — University of California, San Francisco
- Study coordinator: Shiboski, Caroline Helene
Related research
Other NIH-funded projects on the same topics.
-
How cancer cells use exosomes to evade the immune system
This study is looking at how cancer cells use tiny bubbles called exosomes to hide proteins that can keep your immune system from fighting the tumor, and by figuring this out, the researchers hope to help doctors understand why some people respond well to cancer treatments while others don’t, ultimately aiming to creat
-
Reducing harm from smoking using electronic cigarettes
This study is looking at whether using electronic cigarettes can be a safer option for people who smoke traditional cigarettes, by comparing the health effects and exposure to harmful substances between the two.
-
Understanding how knee pain and knee obesity and muscle loss affect knee osteoarthritis
This project looks at how knee swelling, excess knee fat, and muscle loss relate to pain and structural changes in knee osteoarthritis in adults.
-
Cutaneous opioid signals in skin inflammation
A mentor-identified clinician-researcher at UCSF is studying how natural skin opioids regulate itch and pain in inflammatory skin conditions like eczema and hidradenitis, with plans to map where these opioids come from and how they affect skin nerves.
-
Pooling international data to understand long-term bisphosphonate use and atypical femur fractures
This project combines large patient datasets from multiple countries to understand how long-term bisphosphonate use relates to rare hip and thigh bone fractures, helping doctors and patients make safer treatment choices.
-
Airway cell and immune cell talks in lung transplant failure
This grant tests how airway cells and immune cells interact to drive chronic rejection after lung transplant, with the goal of slowing or preventing scar-like damage.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.